NIIMBL Action Plans & Roadmaps

NIIMBL technology action plans and technology roadmaps guide activities related to key biopharmaceutical manufacturing challenges and opportunities.

Antibody Manufacturing for Rapid Response

The NIIMBL Action Plan for Increasing Flexibility of Antibody Manufacturing for Rapid Response aims to accelerate industry adoption of next-generation manufacturing technologies for antibody production to enable rapid response to emerging health needs and speed product time to market.

Download the Antibody Manufacturing Action Plan

NIIMBL Roadmaps

NIIMBL technology roadmaps propose solutions to critical manufacturing challenges in three key topic areas: Antibody-Drug Conjugates (ADC) and Bispecific Antibodies, Gene Therapies, and Vaccines.

About the roadmapping process

The Institute convened subject matter experts from industry, academic institutions, non-profits, and federal agencies to survey the current landscape and identify areas of opportunity for each of these product classes. The process also included participants focused on workforce development and regulatory considerations.

  • The diversity of stakeholders ensured a wide range of perspectives from across the ecosystem.
  • The process was facilitated by the BioPhorum Operations Group.

NIIMBL’s industry roadmap efforts will continue as we address additional topics.  

Download the roadmaps

Download the ADC/Bispecifics roadmap
Download the Gene Therapy roadmap
Download the Vaccines roadmap

Future roadmapping plans

Our industry roadmap efforts will continue as we address additional topics.

  • Experts from NIIMBL member and non-member organizations are invited to contribute.
  • If you are interested in participating, please contact us.

Become a member

We offer a variety of membership options that give you the flexibility to choose your organization’s level of engagement based on technology interests and priorities.